Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection
COVID-19
About this trial
This is an interventional treatment trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
- RT-qPCR SARS-CoV-2 positivity or chest computed Tomography with suspected COVID-19 pneumonia
- Hospitalization by medical emergency staff criteria
Exclusion Criteria:
- Other confirmed viral active and acute infection
Sites / Locations
- Jose Manuel Arreola Guerra
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Hospitalized patients with COVID-19 QTc < 500 mseg
Hospitalized patients with COVID-19 infection with QTc >500ms
Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc < 500 ms could be randomized to hydroxychloroquine, ivermectin or placebo.
Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc > 500 ms could be randomized to ivermectin or placebo.